Latest News

Date Title Topic
05 Jan 2015 FDA Approves Nivolumab for Patients with Advanced, Refractory Melanoma Melanoma - Cancer Immunology and Immunotherapy
24 Dec 2014 FDA Approves Olaparib for BRCA-Mutated Patients with Heavily Pretreated Advanced Ovarian Cancer Personalised medicine - Gynaecologic malignancies - Anticancer agents & Biologic therapy
23 Dec 2014 European Medicines Agency Recommends to Extend Indications for Bortezomib Haematologic malignancies - Anticancer agents & Biologic therapy
22 Dec 2014 European Medicines Agency Recommends a New Indication for Lenalidomide Haematologic malignancies - Anticancer agents & Biologic therapy
19 Jan 2015 Second-Line Treatment with FOLFIRI/Ramucirumab Delays Disease Progression and Extends Overall Survival in Patients With Metastatic Colorectal Cancer Gastrointestinal cancers - Anticancer agents & Biologic therapy
16 Dec 2014 Adaptive Pathways Bioethics, legal and economic issues - Anticancer agents & Biologic therapy
16 Dec 2014 FDA Approves Ramucirumab for Treatment of Metastatic NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
15 Dec 2014 Breast Cancer in Men Breast cancer
12 Dec 2014 FDA Approves Gardasil 9 for Prevention of Certain Cancers Caused by Five Additional Types of HPV Epidemiology/Etiology/Cancer Prevention
11 Dec 2014 Adolescents and Young Adults With ALL Benefit From Paediatric Protocols Cancer in Special Situations - Haematologic malignancies
11 Dec 2014 Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer Lung and other thoracic tumours
10 Dec 2014 PD-1 Blockade Shows Safety and Efficacy in Pretreated Hodgkin Lymphoma Haematologic malignancies - Cancer Immunology and Immunotherapy